SAN DIEGO--(BUSINESS WIRE)--Asante Solutions, Inc., manufacturer of the Asante Snap Insulin Pump, and DexCom, Inc. (NASDAQ: DXCM) announced today their intention to enable the Dexcom mobile app platform, which is currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump. This will be the second insulin delivery device to be integrated into the Dexcom mobile app, which is designed to aggregate glucose and other diabetes-related data from patients’ devices and display the integrated data on a smartphone. In June, Dexcom announced its intention to maintain an “open architecture” approach to diabetes-related data which will include an “Authorized by Dexcom” mark to indicate the compatibility of devices and apps integrating Dexcom CGM data.
“Asante’s mission is to simplify the management of diabetes, both for people with diabetes and their healthcare providers, and this is the next step in doing so,” said David Thrower, CEO of Asante Solutions. Integration with the Dexcom mobile platform is the next step in our commitment to make pump data available where and how a patient will want to view it,” Thrower continued.
“More than ever, we believe that effective diabetes management depends on timely and accurate data. That is why we are excited to complete development of our mobile app and integrate data from the Asante Snap™ Insulin Pump system,” said Kevin Sayer, Dexcom President and Chief Operating Officer.
About Asante Solutions, Inc.
Based in the heart of Silicon Valley, Asante Solutions, Inc. is a privately-held diabetes company. Asante was founded on a belief that life could be made simpler for people with diabetes, and those who love them. For more information, visit www.snappump.com.
About DexCom, Inc.
DexCom, Inc. (www.dexcom.com), headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.
Dexcom Cautionary Statement Regarding Forward Looking Statements
Dexcom is a medical device company with a limited operating history. Successful commercialization of the company’s products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company’s quarterly report on Form 10-Q for the period ending June 30, 2014, as filed with the Securities and Exchange Commission on August 6, 2014.
